Skandinaviska Enskilda Banken Ab (Publ) Iovance Biotherapeutics, Inc. Transaction History
Skandinaviska Enskilda Banken Ab (Publ)
- $21.6 Billion
- Q4 2024
A detailed history of Skandinaviska Enskilda Banken Ab (Publ) transactions in Iovance Biotherapeutics, Inc. stock. As of the latest transaction made, Skandinaviska Enskilda Banken Ab (Publ) holds 155,684 shares of IOVA stock, worth $565,132. This represents 0.01% of its overall portfolio holdings.
Number of Shares
155,684
Previous 113,952
36.62%
Holding current value
$565,132
Previous $1.07 Million
7.66%
% of portfolio
0.01%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding IOVA
# of Institutions
342Shares Held
247MCall Options Held
2.51MPut Options Held
3.5M-
Vanguard Group Inc Valley Forge, PA27.5MShares$99.9 Million0.0% of portfolio
-
Mhr Fund Management LLC New York, NY24.4MShares$88.6 Million24.02% of portfolio
-
Perceptive Advisors LLC New York, NY22.1MShares$80.3 Million5.46% of portfolio
-
Black Rock Inc. New York, NY21.2MShares$77 Million0.0% of portfolio
-
State Street Corp Boston, MA12.2MShares$44.5 Million0.0% of portfolio
About IOVANCE BIOTHERAPEUTICS, INC.
- Ticker IOVA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 157,800,992
- Market Cap $573M
- Description
- Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...